Camlin Fine Sciences Dirección
Dirección controles de criterios 3/4
Actualmente no disponemos de información suficiente sobre el CEO.
Información clave
Ashish Dandekar
Chief Executive Officer (CEO)
₹28.2m
Compensación total
| Porcentaje del salario del CEO | 54.61% |
| Permanencia del CEO | 19.3yrs |
| Participación del CEO | 10.3% |
| Permanencia media de la dirección | 4.7yrs |
| Promedio de permanencia en la Junta Directiva | 5.7yrs |
Actualizaciones recientes de la dirección
Recent updates
Actualización de narrativa • Apr 26
532834: Upcoming Meetings Will Support Bullish Outlook With Stable Forward Assumptions
Analysts have left the Camlin Fine Sciences price target unchanged at ₹182.5, explaining that a slightly lower discount rate and marginally higher profit margin assumptions are balanced by a modestly lower future P/E input. What's in the News Special and Extraordinary Shareholders Meeting scheduled via postal ballot in India on May 7, 2026, indicating upcoming shareholder decisions that may affect the company structure or capital plans (Key Developments).Actualización de narrativa • Apr 11
532834: Upcoming Meetings Will Support Confident Outlook Despite Revised Forecast Assumptions
Analysts have trimmed their price target on Camlin Fine Sciences from ₹235 to ₹182.5. This reflects updated assumptions around fair value, revenue growth, profit margins and future P/E expectations. What's in the News Board meeting scheduled for Feb 13, 2026, to consider and approve the unaudited standalone and consolidated financial results for the quarter and nine months ended Dec 31, 2025 (Key Developments).Actualización de narrativa • Mar 25
532834: Upcoming Results Meeting Will Reinforce Steady Assumptions Supporting Upside Potential
Analysts have kept the fair value estimate for Camlin Fine Sciences steady at ₹235, with only minor tweaks to assumptions on discount rate, revenue growth, profit margin and future P/E, resulting in a largely unchanged price target narrative. What's in the News Board meeting scheduled on February 13, 2026 to consider and approve the unaudited standalone financial results for the quarter and nine months ended December 31, 2025 (company filing).Actualización de narrativa • Mar 10
532834: Scheduled Results Review Will Confirm Steady Assumptions Supporting Upside Potential
Analysts have kept their fair value estimate for Camlin Fine Sciences steady at ₹235, citing largely unchanged assumptions around revenue growth, profit margins and future P/E, with only minor tweaks to the discount rate and valuation inputs. What's in the News Board meeting scheduled for February 13, 2026, to review and approve the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025 (company filing).Actualización de narrativa • Feb 24
532834: Upcoming Results Review Will Support Long Term Upside Potential
Analysts have adjusted their fair value estimate for Camlin Fine Sciences from ₹240 to ₹235, reflecting updated views on the discount rate, revenue growth, profit margin and future P/E assumptions. What's in the News A board meeting is scheduled for February 13, 2026, to consider and approve the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025 (company filing).Actualización de narrativa • Feb 09
532834: Upcoming Board And Director Decisions Will Support Long Term Upside
Analysts have maintained their fair value estimate for Camlin Fine Sciences at ₹240.00, with the small adjustments in discount rate and future P/E assumptions reflecting updated views on risk and valuation drivers rather than a change in the headline price target. What's in the News Board meeting scheduled for February 13, 2026, to consider and approve the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025 (Key Developments).Actualización de narrativa • Jan 25
532834: Director Reappointment And Steady Assumptions Will Support Long Term Upside
Analysts have kept their fair value estimate for Camlin Fine Sciences steady at ₹240.0 per share, with the unchanged target reflecting consistent assumptions on revenue growth, profit margin and future P/E, alongside a slightly updated discount rate input. What's in the News A board meeting is scheduled for Nov 10, 2025, to consider and approve the unaudited standalone and consolidated financial results for the quarter and half year ended Sep 30, 2025, and to discuss other matters (Key Developments).Actualización de narrativa • Jan 11
532834: Governance Continuity And Stable Assumptions Will Support Long Term Upside
Analysts have kept their price target for Camlin Fine Sciences steady at ₹240.00. This reflects updated assumptions around a slightly higher discount rate and fine-tuned estimates for revenue growth, profit margin and future P/E, without a clear tilt in either a more optimistic or more cautious direction.Actualización de narrativa • Dec 24
532834: Share Swap And Governance Stability Will Drive Long Term Returns
Analysts have maintained their price target for Camlin Fine Sciences at ₹240.00, with only marginal tweaks to the underlying model inputs. This reflects steady confidence in the company’s growth and profitability trajectory.Actualización de narrativa • Dec 10
532834: Share Swap Acquisition Will Drive Long Term Returns
Analysts have modestly maintained their outlook on Camlin Fine Sciences, keeping the price target broadly unchanged near ₹240, as small tweaks to the discount rate and forward earnings assumptions continue to support a steady long term growth narrative. What's in the News Board meeting scheduled for November 10, 2025, to approve unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025, and to consider the reappointment of Mahabaleshwar Palekar as a non executive independent director (Key Developments).Actualización de narrativa • Nov 26
532834: Share Swap Acquisition And Margin Expansion Will Drive Future Returns
Analysts have lowered their price target for Camlin Fine Sciences from ₹270 to ₹240. They cite updated estimates that reflect improved profit margins and revenue growth, along with a reduced valuation multiple.Actualización de narrativa • Nov 11
532834: Acquisition Plan Will Drive Shareholder Value Despite Margin Pressure
Analysts have revised their price target for Camlin Fine Sciences downward from ₹295 to ₹270. They cited lower expected profit margins, even though revenue growth is projected to be stronger.Nueva narrativa • Sep 04
Tariff Benefits And Safety Trends Will Boost US And Europe
Key Takeaways Plant restarts and easing exceptional expenses are set to improve margins, with structural growth driven by global demand for compliant, high-quality food additives. Favorable trade barriers and China+1 supply diversification position Camlin Fine Sciences for market share gains, margin expansion, and reduced dependence on legacy products.Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Dec 31 2025 | n/a | n/a | -₹141m |
| Sep 30 2025 | n/a | n/a | ₹187m |
| Jun 30 2025 | n/a | n/a | ₹825m |
| Mar 31 2025 | ₹28m | ₹15m | ₹685m |
| Dec 31 2024 | n/a | n/a | -₹2b |
| Sep 30 2024 | n/a | n/a | -₹2b |
| Jun 30 2024 | n/a | n/a | -₹1b |
| Mar 31 2024 | ₹29m | ₹15m | ₹651m |
| Dec 31 2023 | n/a | n/a | -₹8m |
| Sep 30 2023 | n/a | n/a | ₹350m |
| Jun 30 2023 | n/a | n/a | ₹674m |
| Mar 31 2023 | ₹26m | ₹14m | ₹577m |
| Dec 31 2022 | n/a | n/a | ₹581m |
| Sep 30 2022 | n/a | n/a | ₹628m |
| Jun 30 2022 | n/a | n/a | ₹442m |
| Mar 31 2022 | ₹20m | ₹12m | ₹650m |
| Dec 31 2021 | n/a | n/a | ₹598m |
| Sep 30 2021 | n/a | n/a | ₹465m |
| Jun 30 2021 | n/a | n/a | ₹579m |
| Mar 31 2021 | ₹18m | ₹11m | ₹510m |
| Dec 31 2020 | n/a | n/a | ₹394m |
| Sep 30 2020 | n/a | n/a | ₹291m |
| Jun 30 2020 | n/a | n/a | ₹302m |
| Mar 31 2020 | ₹18m | ₹11m | ₹303m |
Compensación vs. Mercado: La compensación total de Ashish($USD293.70K) está por encima de la media de empresas de tamaño similar en el mercado Indian ($USD174.21K).
Compensación vs. Ingresos: La compensación de Ashish ha sido consistente con los resultados de la empresa en el último año.
CEO
Ashish Dandekar (61 yo)
19.3yrs
Permanencia
₹28,216,000
Compensación
Mr. Ashish Subhash Dandekar serves as the Chairman of Board at Camlin Fine Sciences Limited since June 17, 2021. He has been the Managing Director of Camlin Fine Sciences Limited (formerly known as Camlin...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Chairman & MD | no data | ₹28.22m | 10.34% ₹ 2.4b | |
| MD & Director | 4.9yrs | ₹24.56m | 1.88% ₹ 442.1m | |
| Executive Director of Technical & Executive Director | no data | ₹11.98m | 0.10% ₹ 23.9m | |
| Chief Financial Officer | 9.3yrs | sin datos | sin datos | |
| Chief Operating Officer | 2.4yrs | sin datos | sin datos | |
| Company Secretary | 4.5yrs | ₹1.39m | sin datos | |
| Global Head of IT | no data | sin datos | sin datos | |
| Management Consultant | no data | sin datos | sin datos |
4.7yrs
Permanencia media
58.5yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de 532834 se considera experimentado (4.7 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Chairman & MD | 19.3yrs | ₹28.22m | 10.34% ₹ 2.4b | |
| MD & Director | 11.8yrs | ₹24.56m | 1.88% ₹ 442.1m | |
| Executive Director of Technical & Executive Director | 7.9yrs | ₹11.98m | 0.10% ₹ 23.9m | |
| Independent Director | 1.3yrs | ₹600.00k | 0.068% ₹ 16.0m | |
| Non-Executive Non-Independent Director | 5.8yrs | sin datos | sin datos | |
| Non-Executive Independent Director | 4.6yrs | ₹2.45m | sin datos | |
| Non-Executive Non-Independent Director | 8.6yrs | ₹700.00k | 1.57% ₹ 369.9m | |
| Independent Director | 5.7yrs | ₹2.46m | sin datos | |
| Independent Non-Executive Director | 5.4yrs | ₹2.64m | 0.0031% ₹ 734.5k | |
| Independent Director | 6.8yrs | ₹2.18m | sin datos | |
| Independent Director | 1.2yrs | ₹125.00k | sin datos | |
| Non-Executive Non-Independent Director | 1.2yrs | sin datos | sin datos |
5.7yrs
Permanencia media
59.5yo
Promedio de edad
Junta con experiencia: La junta directiva de 532834 se considera experimentada (5.7 años de antigüedad promedio).
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/05/22 14:44 |
| Precio de las acciones al final del día | 2026/05/22 00:00 |
| Beneficios | 2025/12/31 |
| Ingresos anuales | 2025/03/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Camlin Fine Sciences Limited está cubierta por 9 analistas. 2 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Ankur Periwal | Axis Capital Limited |
| Abhishek Navalgund | Centrum Broking Limited |
| Satish Kumar | CGS International |